

UNITED STATES DISTRICT COURT  
FOR THE SOUTHERN DISTRICT OF NEW YORK

CHARLES SEIFE,

Plaintiff,

*v.*

FOOD AND DRUG ADMINISTRATION and  
DEPARTMENT OF HEALTH AND HUMAN  
SERVICES,

Defendants,

and

SAREPTA THERAPEUTICS,

Intervenor-Defendant.

Case No. 1:17-cv-3960

May 29, 2018

**DECLARATION OF PETER LURIE**

I, PETER LURIE, MD, MPH, declare as follows:

1. I, Peter Lurie, am President of the Center for Science in the Public Interest, former Associate Commissioner for Public Health Strategy and Analysis at the Food and Drug Administration (FDA) and the agency lead on transparency activities, former medical school professor, and a physician and epidemiologist. I submit this expert declaration in support of plaintiff Charles Seife's opposition to the government's and intervenor-defendant Sarepta Therapeutics' (Sarepta) motions for summary judgment and in support of Seife's cross-motion for summary judgment. I was not myself involved in the decision-making process surrounding the approval of Exondys 51; this declaration is based solely on facts in the public record. The opinions and conclusions derive from my more than thirty years of experience in public health, applied the public record cited below. I was not compensated for this declaration.

## I. QUALIFICATIONS

2. I am currently President of the Center for Science in the Public Interest, a non-profit watchdog organization in the public health and nutrition space. Prior to assuming this position, I served for eight years at the FDA in various capacities, including as the Associate Commissioner for Public Health and Strategy and Analysis, and the Associate Commissioner for Policy and Planning, where I oversaw a 101-person, \$16.3 million unit responsible for policy formation, regulation, guidance development, quantitative analysis, and strategic planning. During my tenure at the FDA, I was the agency lead on transparency activities as well as on streamlining expanded access procedures for patients seeking access to experimental, typically unapproved, medications. I was also the agency representative to the Department of Health and Human Services (HHS) on Data Management and Verification, Evaluation and Evidence, and Social Determinants of Health. I coordinated agency responses to reports by the Government Accountability Office and HHS Office of the Inspector General. While at the FDA, I received over thirteen awards for my work, including the HHS Secretary's Award for Distinguished Service to the Opioid Initiative Team and the FDA Commissioner's Special Citation "for promoting public health through increasing the transparency of animal drug sales to support the public's interest in antimicrobial resistance." I also authored over eight reports for the US government on divergent results between Phase 2 and Phase 3 clinical trials, prescription drug abuse and addiction, the public health evidence for oversight of laboratory developed tests, the silent epidemic of viral hepatitis, and a review of the FDA's approach to medical product shortages, as well as numerous reports in the peer-reviewed medical literature, including several on transparency.

3. Before my work at the FDA, I was Deputy Director at Public Citizen's Health Research Group, a consumer advocacy organization, where I developed and promoted advocacy positions on a wide variety of public health issues, including researching pharmaceutical safety and efficacy, and

testified before Congress on eleven occasions, including on pediatric drug and device policy. I appeared approximately fifty times before various federal and public health committees and also testified before the FDA's Transparency Task Force.

4. I have also been a Visiting Assistant Research Scientist at the University of Michigan Institute for Social Research, where I was the principal investigator of a National Institutes of Health (NIH) funded multi-site case control study of needle exchange program effectiveness; an Assistant Professor at the University of California, San Francisco in the Departments of Epidemiology and Biostatistics and of Family and Community Medicine; and have held adjunct faculty positions at Johns Hopkins Bloomberg School of Public Health and George Washington University School of Public Health.

5. I completed multiple post-doctoral fellowships at the University of California, San Francisco where I also did a medical residency in the Family Practice program. I did a second residency at the University of California, Berkeley in Preventive Medicine and also received my Masters in Public Health there in Epidemiology. I obtained my medical degree from Albert Einstein College of Medicine and my undergraduate degree from Cornell University, where I graduated with distinction.

6. I maintain an active medical license in the District of Columbia.

7. I have published over a hundred articles in medical journals, including about access to experimental medications, clinical trial design, researcher conflict of interest, research ethics, drug efficacy and safety, cost-effectiveness, HIV prevention, international health, and drug promotion and labeling. These include an article on FOIA and clinical data.<sup>1</sup>

---

<sup>1</sup> Peter Lurie & Allison Zieve, *Sometimes the Silence Can Be Like the Thunder: Access to Pharmaceutical Data at the FDA*, 69 *Law and Contemporary Problems* 85 (2006) (Kenney Decl., Ex. BB, 52-64).

## II. PUBLIC HEALTH INTEREST IN RELEASE OF THE WITHHELD INFORMATION

### A. EFFICACY

8. When researchers design trials, they pre-specify the study measures of efficacy, also known as “endpoints.” Primary endpoints are typically measures of clinical effectiveness, by which the efficacy of the drug is gauged. Primary endpoints are designed to measure the most important (or primary) question asked by the clinical trial. Many trials, including Studies 201 and 202, have “secondary” outcome measures too; these are also designed to measure efficacy but are considered less critical to the overall assessment of the drug’s effectiveness. It would be virtually impossible for a drug to be approved without revealing the “primary endpoints” to the FDA and the public, generally through the approval package, the drug label, advisory committee testimony, journal publications, [www.clinicaltrials.gov](http://www.clinicaltrials.gov), or Securities and Exchange Commission filings. This is particularly true, where, as here, there are certain standardized endpoints, such as the 6-minute walk test, which are routinely used by researchers to test the effectiveness of drugs used to treat muscular dystrophy.

9. In assessing the effectiveness of a drug, it is essential to understand the outcomes for all secondary measures. There are circumstances where the primary outcome measures suggest a drug is ineffective whereas the secondary outcome measures indicate the drug is actually effective. In such a case, as is true here given the weak evidence of efficacy demonstrated on Sarepta’s primary endpoint, it would be important for all secondary outcome measures to be made public. On the other hand, if the primary outcome did not provide clear evidence of effectiveness, and only one secondary endpoint of several were positive, that would open the FDA’s approval decision to legitimate question. It is therefore important to be transparent about all secondary outcomes, so that positive ones can be assessed in context.

10. Access to Clinical Study Reports (CSRs) data could also show whether a researcher has engaged in retrospectively highlighting positive outcomes to make a drug appear more effective than it actually is. This is a potential concern in this case, as the sponsor converted the 6-minute walk test from an “exploratory” to a secondary endpoint. In the world of medical research, researchers all too often skew clinical trial reports to make drugs seem more effective than they are. For example, I wrote a journal article about a paper about a medical device that reported certain, but not all, secondary endpoints as evidence of the efficacy of its device.<sup>2</sup> I obtained information the company had presented to an FDA Advisory Committee that enabled me to show that endpoints were disproportionately published if they achieved statistical significance—indeed, at a rate three times more than secondary endpoints that did not achieve statistical significance. Given the controversy surrounding Exondys 51’s approval, it is in the public interest to release the secondary endpoint data withheld in the CSR to ensure that the data were fairly reported by Sarepta. Release of the withheld data would also allow researchers to validate the trials by seeing if Sarepta made any obvious analytical errors with respect to setting and testing the secondary endpoints. and if the endpoints support efficacy.

11. When a researcher tests numerous hypotheses instead of just one or two, there is a higher likelihood that one of those many endpoints will reach statistical significance by chance, rather than reflecting a true phenomenon. Releasing the results data for all secondary endpoints would allow doctors and patients, and the public at large, to understand positive secondary outcomes in their proper statistical context, and to prevent Sarepta from “cherry picking” data.

## **B. SAFETY**

12. Adverse Events (AEs) are negative reactions experienced by patients that may or may not be caused by the drug they are taking. There is a substantial public health interest in release of the

---

<sup>2</sup> Eunice Yu & Peter Lurie, *Transcranial Magnetic Stimulation Not Proven Effective*, *Biological Psychiatry* 2010;67:e13.

requested Adverse Event (AE) and other safety information for Exondys 51 because such transparency would promote informed doctor-patient decision-making about the drug. This is particularly the case where, as here, there is considerable doubt regarding whether the drug's risks outweigh its benefits.

13. Safety data from CSRs are particularly valuable to patients and researchers. CSRs, which form the primary basis of FDA approval, contain the results of randomized, controlled clinical studies. Clinical studies generally contain data on AEs for patients in two separate, randomized groups: those in the treatment arm of the study who received the drug and those in the control (or comparison) group who received a placebo or an alternative therapy. Because of this randomization, researchers can draw inferences about whether taking a drug *caused* an AE or not. By contrast, the other source of pre-market safety data available to researchers, the so-called safety database, contains a large amount of non-randomized data, so it does not provide the same reliable information about causation. Here, providing access to the CSRs for Study 201 and 202 would let doctors and patients better assess whether particular AEs were likely caused by Exondys 51.

14. Although post-market AE data are publicly available for all approved drugs, the pre-market AE data that are being withheld for Studies 201 and 202 have unique value because, in addition to being randomized, they contain more reliable estimates for both the numerator (the number of patients who experienced each AE) and the denominator (the number of patients in each arm of the trials).

15. The number of AEs (the numerator) is known to be significantly underreported in post-market data, since the reporting is generally done on a voluntary basis and without substantial detail. In contrast, for AEs in pre-market clinical trials, there will be considerable detail about the number of AEs through patient diaries. The number of patients taking the drug (the denominator) is also more accurate in pre-trial clinical study data. Researchers are often forced to resort to proprietary

prescription data, which are difficult to obtain and lacking in detail. In contrast, for AEs in pre-market clinical trials, there will be considerable detail about the number of patients taking the drug through pill counts and/or patient diaries, as well as for how long they took it.

16. By corollary, any estimate of the fraction of patients experiencing the AE over time drawn from post-market data will be less reliable than that drawn from the clinical trial.

17. Moreover, there is generally no control group in the post-market data, so it is not possible to draw conclusions about whether the frequency of AEs is elevated for those taking the drug. While the FDA released the denominator from the clinical trials (12 patients), it has withheld the numerator (the number of patients who experienced particular AEs). Without both numbers, the frequency of AEs cannot be estimated, nor can doctors, researchers, and patients independently assess whether the drug caused those AEs. Given the FDA's approval of Exondys 51, it is likely that, for ethical reasons, Study 201 may remain the only source of randomized, placebo-controlled data on AEs for patients taking exon 51-skipping drugs.

18. Although some safety data are on a drug's label, CSRs contain additional information about those AEs, such as duration and narrative descriptions. CSRs can also reveal other AEs not listed on the label. Release of this information may allow clinicians to monitor their patients for the AEs observed in the trial, diagnose the AE sooner, and discontinue the drug or treat the AE more effectively. When doctors and patients decide whether to use a drug, they weigh the potential benefit against the potential harm. Disclosure of AEs not on the label is especially important where, as here, there are material concerns about a drug's efficacy, and the benefits of taking a drug are in question.

### **C. OTHER CONSIDERATIONS**

19. Patients join clinical trials not merely for personal reasons, but for altruistic ones as well: to make data about a drug available to other prospective patients with the same condition in order to improve their health outcomes. To the extent that CSR data are not fully exploited, this is a violation

of participants' desires to maximize the benefits and minimize risks posed by the drug to subsequent patients who may be unknowingly exposed to risk. Indeed, for drugs where the efficacy is in doubt, reporting CSR results fully informs both the conduct of ongoing clinical trials, as well as prescribing decisions should the product be approved.

20. Finally, the more information about a drug is made public, the more likely it is to improve public health and save patient lives. The more pairs of responsible eyes there are on the data, the more likely it is that researchers will have unique insights into a drug's profile. All of this is especially true where, as here, there is controversy or competing interpretation of contested data. In looking at the data for Studies 201 and 202, researchers may have new interpretations or questions that tilt the balance in terms of the advisability or content of warning labels, or even pulling a drug from the market, thereby preventing large numbers of patients from being exposed to a potentially ineffective or dangerous drug.

### **III. RELEASE OF THE WITHHELD INFORMATION WOULD BE UNLIKELY TO BE OF AFFIRMATIVE USE TO SAREPTA'S COMPETITORS**

21. Sarepta claims that disclosure would allow other companies to use its analytic methods, but this has no merit as the relevant disclosures have already been divulged through the label, the Action Package, and the Advisory Committee materials and hearing. It is very difficult to believe that the statistical methods are not generally known, especially in light of the FDA's release of additional information about the drug when it was approved. Indeed, the FDA has already released a Statistical Review of Sarepta's analysis,<sup>3</sup> and there is no evidence that releasing the additional withheld details relating to Sarepta's analysis will be of affirmative use to Sarepta's competitors.

---

<sup>3</sup> See Xiang Ling, Office of Biometrics, US Food and Drug Administration, *Statistical Review and Evaluation [of Exondys 51]* (2016), [https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2016/206488Orig1s000StatR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206488Orig1s000StatR.pdf) (Kenney Decl., Ex. R, 2-35).



22. Sarepta argues that they are studying “dosing” and that this information is valuable to competitors, but information about dosing is already part of the label and thus known to competitors. The label specifies how frequently to administer a dose, in what amount, and how to administer the dose, including how to prepare it, if necessary.<sup>4</sup> It strains credulity that releasing the additional withheld details relating to Sarepta’s dosing will be of affirmative use to competitors.

23. Sarepta argues that data about its clinical endpoints would be valuable to competitors, but the efficacy endpoints that are most commercially valuable are already known in the research community, among university researchers and academics. Moreover, as noted, they have already been disclosed through the approval package, the drug label, advisory committee testimony, journal publications, and [www.clinicaltrials.gov](http://www.clinicaltrials.gov). Their main clinical endpoint, the 6-minute walk test, which measures how far (in meters) a patient can walk in 6 minutes, is widely used in the field, and its methods are generally understood. Thus, it is extremely improbable that the data for the 6-minute walk test would be of great commercial value, as the company is one of many in the field using this measure. To the extent Sarepta did, somehow, modify the generally accepted methods of the 6-minute walk test, that is still important on balance for patients, doctors, and researchers to know, so that the data can be understood and compared to other studies on an apples-to-apples basis.

24. Sarepta argues that the Appendices from Studies 201 and 202 could be used as a “historical control” by competitors. Historical controls are “control groups” that are not from the same study but contain detailed information about patients in other studies that are close in demographic information and disease status to the treatment group of the study in question. It is my understanding that Seife is seeking de-identified data from Studies 201 and 202, where information related to patient

---

<sup>4</sup> See *Exondys 51 (eterplirsen) Injection Label*, [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/206488lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206488lbl.pdf) (last accessed May 21 2018) (Kenney Decl., Ex R, 38-40).

age, height, weight, and demographic information is redacted to preserve patient privacy. But such redacted data would not be reliable enough to support FDA approval based on the FDA's extensive requirements for historical controls in studies of Duchenne Muscular Dystrophy that Sarepta itself cites, which mandate patients be compared to an extremely similar population demographically.<sup>5</sup> The Guidance states that "it would be critical to establish that the control group was prospectively well matched to the treatment group across important baseline and prognostic variables, including age, baseline value of the primary efficacy measure and other measures of disease stage, type and intensity of supportive care, dose and duration of concomitant pharmacotherapies, and genotype, among others."<sup>6</sup> Thus, Sarepta cannot demonstrate that release of the de-identified information could be used as a historical control in any meaningful way.

25. For the same reasons, it is unlikely that release of the de-identified information could be used to create a "head to head" trial with Exondys 51. Sarepta implies two possibilities: (1) A competitor could (according to Sarepta) take information related to Sarepta's treatment groups in Studies 201 and 202 and compare that information to its own drug to draw a conclusion about which drug is better; or (2) A competitor could (again according to Sarepta) take information related to the placebo group and use that as a control group for their trial. But, like Sarepta's historical control theory, in order to do this to the level of detail required for FDA approval, a competitor would need to have information about the patient's demographics, age, weight, etc., which Seife is not seeking. This is because the FDA in its guidance specifies the groups must be provably similar with regard to patient population being treated.<sup>7</sup>

---

<sup>5</sup> US Food & Drug Administration, *Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry* (2018), <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM450229.pdf> (Kenney Decl., Ex. U, 9).

<sup>6</sup> *Id.*


<sup>7</sup> *Id.*

26. Finally, while Sarepta does not state this clearly in its briefing, its arguments at bottom consist of advocating that competitors conduct trials that are “dead ends” so Sarepta can preserve its competitive advantages, and thereby expose pediatric patients—children—to trials that are expected to be useless and that carry risk because they could be accompanied by AEs. Knowingly performing unnecessary experiments on patients is unethical and is a violation of the Declaration of Helsinki, an international accord that governs ethics in medical trials, which requires that “Medical research involving human subjects may only be conducted if the importance of the objective outweighs the risks and burdens to the research subjects.”<sup>8</sup>

\*\*\*

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury that the foregoing is true and correct.

Executed this 29st day of May 2018, in Washington, DC.

A handwritten signature in blue ink that reads "Peter Lurie". The signature is written in a cursive style and is positioned above a horizontal line.

---

Peter Lurie, MD, MPH

---

<sup>8</sup> World Medical Association, Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects, 18th WMA General Assembly, Helsinki, Finland, (June 1964), <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/> (Kenney Decl., Ex. HH, 4).

**CURRICULUM VITAE**  
**PETER GRANT LURIE, MD, MPH**

1820 Ontario Place, NW  
Washington, DC 20009  
Telephone: [REDACTED] (work)  
Cell: [REDACTED]  
Fax: [REDACTED]  
Email: [REDACTED]  
[REDACTED] (personal)

Birthdate: [REDACTED], 1959  
Birthplace: Cape Town, South Africa  
Citizenship: United States

**PROFILE**

- Highly trained physician and epidemiologist with distinguished academic career
- Long experience promoting the public health from within and outside government
- Proven leader with strong ability to work with a wide array of people

**WORK EXPERIENCE**

***President and Executive Director*** September 2017-present

Center for Science in the Public Interest

Led 45-person, \$15 million public interest group advocating for nutrition and other public health issues

Accomplishments

- Food-related advocacy
  - Pressured FDA to finalize proposals on menu labeling, nutrition facts labels
  - Submitted comments to USDA on several food safety proposals
  - Facilitated litigation against leading food corporations for misleading advertising or promotion
  - Produced report on sesame allergy
- Other advocacy
  - Defended FDA against potential outsourcing of certain drug and device approval functions
  - Produced report on dietary supplement companies making opioid withdrawal treatment claims, leading to FDA enforcement action
  - Led or participated in campaigns to prevent three administration health nominees
- Administrative
  - Reorganized the entire office along functional lines
  - Initiated hiring of new Chief Operating Officer
  - Clarified organization's gift-giving policy

***Associate Commissioner for Public Health Strategy and Analysis*** September 2014-August 2018

U.S. Food and Drug Administration, Silver Spring, MD

Directed staff responsible for quantitative and qualitative analyses of proposed and existing agency policies

*Accomplishments*

- Provided rapid policy assessment on developing policy issues
  - Agency lead on antimicrobial resistance
  - Hydrocodone upscheduling
  - Led HHS subcommittees on opioids and marijuana
  - Led HHS working group on naloxone, including leading Naloxone App Prize Competition
  - Pediatric oxycodone prescribing
  - Publication rates for post-marketing studies
  - Agency lead on liaison with GAO and HHS OIG
  - Appearance conflicts on FDA advisory committees
  - State requirements for opioid-related CME
  - Laboratory-developed tests
  - Use of decision analysis to aid Agency decision-making
  - Morcellation and risk of uterine sarcoma
  - Agency lead on transparency activities
  - Agency lead on streamlining expanded access procedures, including Congressional testimony
  - Acquired poison control center data for FDA
  - President's Emergency Plan for AIDS Relief (PEPFAR) evaluation
  - Investigation of events surrounding NIH Pharmaceutical Development Section
  - Agency representative to HHS committees on Data Management and Verification, Evaluation and Evidence, and Social Determinants of Health
- Reviewed and cleared Agency documents
  - Regulations and guidances
  - Annual Agency reports to Congress
  - Agency correspondence with outside parties and other Federal agencies
  - Agency policy on Federal legislative proposals
- Coordinated Agency responses to reports by Government Accountability Office and Health and Human Services Office of the Inspector General

***Associate Commissioner for Policy and Planning*** January 2014-September 2014

***Acting Associate Commissioner for Policy and Planning*** September 2012-January 2014

U.S. Food and Drug Administration, Silver Spring, MD

Directed 101-person, \$16.3 million unit responsible for leading policy formulation, regulation and guidance development and strategic planning

*Accomplishments*

- Directed Immediate Office and oversaw budget, personnel policies and overall performance of Office of Planning and Office of Policy, in collaboration with Assistant Commissioners

- Co-led quarterly FDA-Track meetings
- Provided rapid policy assessment on developing policy issues
  - Caffeinated beverages
  - Pharmacy compounding
  - Sodium content of food
  - Arsenic in animal feed, apple juice and rice
  - Fish consumption by pregnant and breastfeeding women
- Reviewed and cleared Agency documents
  - Regulations and guidances
  - Annual Agency reports to Congress
  - Agency correspondence with outside parties and other Federal agencies
  - Agency policy on Federal legislative proposals
- Coordinated Agency responses to reports by Government Accountability Office and Health and Human Services Office of the Inspector General

***Senior Advisor, Office of Policy and Planning***

December 2009-September 2012

U.S. Food and Drug Administration, Silver Spring, MD

Provided technical and policy assistance to the Associate Commissioner for Policy and Planning at a large Federal agency, including leading specific agency studies and initiatives  
*Accomplishments*

- Researched and contributed to the development of multiple Agency policies
  - Antibiotic resistance
  - Drug shortage programs
  - Access to Poison Control Center data
  - Blood banking metrics
  - Infant formula claims
  - Human breastmilk banking
  - Regulation of nicotine-containing products
  - Mentholated tobacco products
  - Device issues in Agency user fee reauthorization legislation
  - Rotavirus vaccine contamination
- Detailee to Center for Tobacco Products
  - Represented Agency in discussions with U.S. Trade Representative on TransPacific Partnership trade agreement
  - Organized first International Tobacco Regulators' Conference
  - Developed confidentiality commitments with foreign countries
  - Formulated government response to clove tobacco litigation
- Represented Agency on Health and Human Services and international committees
  - Behavioral Health Coordinating Committee (co-chaired Prescription Drug Abuse Subcommittee and Naloxone Working Group)
  - Hemoglobinopathies
  - Interagency Work Group on Healthcare Quality
  - Prevention policy
  - Healthcare-associated infections
  - Epilepsy
  - Viral hepatitis

- Measurement Policy Council
- World Economic Forum's Healthy Living Charter
- Co-chaired Research Involving Human Subjects Committee

***Deputy Director***

August 2000-November 2009

***Medical Researcher***

July 1998-August 2000

Public Citizen's Health Research Group, Washington, DC

Developed and promoted advocacy positions on a wide variety of public health issues for a leading national consumer advocacy organization.

***Accomplishments***

- Researched, developed and promoted the organization's public health advocacy positions
  - Pharmaceutical safety and efficacy
  - Medical devices
  - Healthcare delivery policy
  - Food safety
  - Occupational safety and health
- Testified before Congress on 11 occasions
  - HIV prevention policy
  - Clinical trial ethics
  - Mad Cow Disease policy
  - Pharmaceutical company payments to physicians
  - Direct-to-consumer advertising
  - Access to medicines in the developing world
  - Pediatric drug and device policy
- Approximately 50 appearances before various Federal and other public committees
- Led development of and co-authored Worst Pills, Best Pills, a 1000-page consumer guide to medications
- Over six dozen articles and opinion pieces in Public Citizen and other lay publications
- Over two dozen letters to the editor in major newspapers
- Lead role in personnel management, budget development and website promotion
- Wrote and was awarded grants to support program activities from the Greenwall Foundation, Open Society Institute, Irene Diamond Foundation, Park Foundation and Public Welfare Foundation
- Numerous national media appearances

***Visiting Assistant Research Scientist***

July 1997-December 1999

University of Michigan Institute for Social Research, Residential College and Inteflex Combined Undergraduate-Medical School Program, Ann Arbor, MI

Conducted cutting-edge research in HIV epidemiology and prevention policy in the U.S. and abroad and developed research-based public health activism course for undergraduates.

***Accomplishments***

- Principal investigator for National Institutes of Health-funded multi-site case-control study of needle exchange program effectiveness
- Designed, conducted and published studies of HIV prevention programs
  - HIV prevention among injection drug users
  - Non-occupational post-exposure prophylaxis
- Peer-reviewed publications with activist course students
  - International tobacco labeling
  - Sex education information on the Internet
  - Hepatitis B vaccination attitudes and practices among college students

***Assistant Professor***

July 1993-December 1998:

University of California, San Francisco Department of Epidemiology and Biostatistics, Department of Family and Community Medicine and Institute for Health Policy Studies, San Francisco, CA

Conducted cutting-edge research in HIV epidemiology and prevention policy in the U.S. and abroad and provided clinical services and instruction at major urban hospital.

***Accomplishments***

- Principal investigator on first comprehensive Federally funded study of needle exchange programs
- Designed, conducted and published numerous studies of HIV prevention programs
  - HIV prevention among injection drug users
  - Cost-effectiveness of HIV counseling and testing policies
  - Ethics of HIV vaccine trials in developing countries
  - Impact of macro-economic policies on HIV dissemination
- Acted as mentor for visiting HIV prevention scholars from developing countries and designed, conducted and authored studies based on research conducted in Africa, Asia and Latin America
- Elected to Center for AIDS Prevention Studies Executive Committee
- Co-directed Clinical Research Training Program for medical fellows

**ADJUNCT FACULTY POSITIONS**

- 2008-present: Associate, Johns Hopkins Bloomberg School of Public Health
- July 2006-2013: Associate Professorial Lecturer, George Washington University School of Public Health and Health Sciences Environmental and Occupational Health
- April 2005-June 2006: Adjunct Associate Professor, George Washington University School of Public Health and Health Sciences Environmental and Occupational Health

**EDUCATION**



*Post-doctoral*

- Pew Health Policy Research Fellow, University of California, San Francisco, 1990-1993
- Traineeships in AIDS Prevention Studies Fellow, Center for AIDS Prevention Studies, University of California, San Francisco, 1990-1993
- Clinical Fellow, Department of Family and Community Medicine, University of California, San Francisco, 1990-1993
- Masters in Public Health, University of California, Berkeley, Epidemiology, May 1991

*Residencies*

- University of California, Berkeley, Preventive Medicine Residency Program, 1990-1992
- University of California, San Francisco, Family Practice Residency Program, 1987-90

*Medical School*

- Albert Einstein College of Medicine, Bronx, NY, M.D., May 1987

*Undergraduate*

- Cornell University, Ithaca, NY, A.B. Chemistry, June 1982  
Graduated with Distinction; Dean's List five times

*Secondary*

- Brighton High School, Rochester, NY, High School Diploma, June 1978
- Herzlia School, Cape Town, South Africa, 1966-1976

**LICENSURE**

- Active District of Columbia Medical License, 2000-present (License number: MD33864)

**AWARDS**

- Food and Drug Administration Commissioner's FDA Leveraging/Collaboration Award "For outstanding teamwork and collaboration in acquiring FDA Agency-wide real-time access to the National Poison Data System which will strengthen FDA's product safety surveillance to protect public health," 2017
- Food and Drug Administration Commissioner's Group Recognition Award "For conceiving and conducting the 2016 FDA Naloxone App Competition innovatively addressing the opioid epidemic by connecting individuals carrying naloxone with those suffering an opioid overdose," 2017

- Food and Drug Administration Commissioner’s Group Recognition Award “For outstanding communications surrounding the FDA’s Opioid Action Plan,” 2016
- Food and Drug Administration Commissioner’s Group Recognition (Crosscutting) Award “For superior teamwork in streamlining the application process for FDA’s single patient expanded access program,” 2016
- Food and Drug Administration Commissioner’s Group Recognition (Crosscutting) Award “For their vision and collaboration in developing and launching a new website section to serve as FDA’s Expanded Access Web Portal,” 2016
- Health and Human Services Secretary’s Award for Distinguished Service to the Opioid Initiative Team, 2015
- Food and Drug Administration Commissioner’s Group Recognition Award (Crosscutting) “For superior teamwork in proactively and collaboratively expediting development and availability of medical products in support of FDA’s response to the West Africa Ebola epidemic,” 2015
- Center for Devices and Radiological Health Director’s Excellence in Postmarket Safety Award “For rapid response to a postmarket safety signal [morcellation] of public health significance,” 2015
- Food and Drug Administration Commissioner’s Group Recognition (Crosscutting) Award “For rapid and comprehensive action to protect the public and FDA employees from potential exposure to infectious and toxic agents [the discovery of smallpox on the National Institutes of Health campus], and prevent future incidents,” 2015
- Food and Drug Administration Commissioner’s Special Citation “For promoting public health through increasing the transparency of animal drug sales to support the public’s interest in antimicrobial resistance,” 2015
- Food and Drug Administration Commissioner’s Special Recognition Award “For organizing and executing the Third Annual FDA Health Professional Organization Conference fostering dialogue and encouraging collaboration to promote public health.” 2015
- Food and Drug Administration Commissioner’s Group Recognition Award to the CT Colonography Advisory Committee Meeting Team, 2014
- Center for Drug Evaluation and Research Director’s Award for Team Excellence “For outstanding team performance in evaluating complex scientific, public health, and regulatory issues related to the safety of extended-release and long-acting opioid analgesics,” 2014
- Food and Drug Administration Commissioner’s Special Citation “For outstanding performance, tireless dedication to duty and steadfast commitment to protecting the nation’s public health responding to the 2012 multi-state meningitis outbreak,” 2013
- Food and Drug Administration Commissioner’s Special Citation “For outstanding leadership, innovation, organizational skills and collaboration in creating the inaugural World Health Organization/FDA International Tobacco Regulators’ Conference,” 2012

- Center for Tobacco Products Director’s Special Citation “For leadership and expertise in assisting CTP to develop and implement an international policy agenda to support the Family Prevention and Tobacco Control Act,” 2011
- Appointed member of Centers for Disease Control Blue Ribbon Panel on Vaccine Safety, 2004
- Appointed member of advisory group on Mad Cow Disease to Health and Human Services Secretary Tommy Thompson, 2001
- Appointed member U.S. Food and Drug Administration Advisory Committee on Transmissible Spongiform Encephalopathies, 1998-2001
- Winner, Alfred R. Lindesmith Award for excellence in scholarship, Drug Policy Foundation, 1997
- Winner, “Activist of the Year,” ACTUP Golden Gate, 1996
- Named one of the “50 Most Innovative U.S. AIDS Researchers,” Poz Magazine, 1996
- Plaque of Appreciation, Colorado Governor’s AIDS Council, 1996
- Nominated for Heinz Award, 1995, 1996, 1997
- Winner, Project Censored’s “Best Censored Story of 1994”
- Nominated for UCSF Chancellor’s Award for Community Service, 1992
- Member, San Francisco Mayor’s Budget Task Force, 1991
- International Health Fellowship Award, 1985
- Phi Beta Kappa, 1982

#### **HEALTH-RELATED FOREIGN TRAVEL**

- 2016: India – U.S. government representative to Government of India/WHO meeting on antimicrobial resistance, Delhi
- 2008: Germany – Invited plenary speaker at Health Action International Europe Annual Meeting, Berlin
- 2008: Japan – Invited speaker at 10<sup>th</sup> Annual Medwatcher Symposium, Tokyo
- 2003: Canada – Society for General Internal Medicine Annual Meeting, Vancouver
- 2002: Brazil – Invited speaker at International Association of Bioethics meeting, Brasilia  
Switzerland – Delegate to Council for International Organizations of Medical Sciences meeting, Geneva
- 1999: Nigeria – Site visit to team conducting peer intervention for young adults
- 1998: Brazil – Invited speaker at International Harm Reduction Conference, Sao Paulo
- 1997: Kenya – Site visit to team researching risk behaviors among adolescents at truck stops on Trans-Africa Highway
- 1997: Cote d’Ivoire – Invited speaker at International Conference “Information Research and Action Programme on HIV/AIDS, STDs and TB,” Abidjan.
- 1996: Brazil – Invited speaker at International Conference “Drugs: Multidisciplinary Debate,” Sao Paulo
- 1995: Belgium – Invited speaker at World AIDS Day Forum, Instituut voor Tropische Geneeskunde, Antwerp

- 1995: Brazil – Site visit to two teams implementing interventions to prevent HIV among injection drug users -- Invited speaker at “Conference on the Use and Abuse of Drugs,” Salvador, Bahia
- 1994: Zambia – Site visit to team investigating relationship between “dry sex” and HIV transmission
- 1993: Switzerland – Consultant to World Health Organization on ethical, social and behavioral aspects of HIV vaccine trials in developing countries
- 1992: England, Netherlands – Visited needle exchange programs
- 1992: Zambia – Site visit to team investigating relationship between “dry sex” and HIV transmission
- 1992: Kenya – Investigated conduct of local pharmaceutical companies
- 1989: Bolivia – Trained primary health care workers; provided clinical care
- 1987: South Africa – Occupational health research on AIDS, lead exposure and the Machinery and Occupational Safety Act; trained primary health care workers; clinical practice in urban and rural settings
- 1986: Netherlands – Researched pharmacology and third world marketing of anabolic steroids
- 1984: Cuba – Attended Colloquium on Occupational Respiratory Disease

#### **FOREIGN LANGUAGES**

- Hebrew (written and spoken)
- Afrikaans (written and spoken)
- Spanish (intermediate)
- Dutch (beginner)
- Portuguese (beginner)
- French (beginner)
- Russian (beginner)

#### **REFERENCES (Contact information available upon request)**

David Michaels, PhD  
Department of Environmental & Occupational Health  
Milken Institute School of Public Health, George Washington University  
Former Assistant Secretary of Labor for Occupational Safety and Health

Margaret Hamburg, MD  
Foreign Secretary, National Academy of Medicine  
Former Commissioner, Food and Drug Administration

Joshua M. Sharfstein, MD  
Associate Dean, Public Health Practice & Training  
Johns Hopkins Bloomberg School of Public Health  
Former Secretary of Health, State of Maryland

## **REPORTS FOR THE U.S. GOVERNMENT**

Protecting Our Infants Act: Report to Congress, Subcommittee on Prescription Drug Abuse, Behavioral Health Coordinating Council, U.S. Department of Health and Human Services, January 19, 2017.

22 Case Studies Where Phase 2 and Phase 3 Trials had Divergent Results, U.S. Food and Drug Administration, January 18, 2017.

Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. U.S. Department of Health and Human Services, November 2016.

National Heroin Task Force Final Report and Recommendations, Office of National Drug Control Policy, December 31, 2015.

The Public Health Evidence for FDA Oversight of Laboratory Developed Tests: 20 Case Studies. Office of Public Health Strategy and Analysis, Office of the Commissioner, Food and Drug Administration, November 16, 2015.

Addressing Prescription Drug Abuse in the United States Current Activities and Future Opportunities. Behavioral Health Coordinating Committee, Prescription Drug Abuse Subcommittee, U.S. Department of Health and Human Services, September 2013.

Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care & Treatment of Viral Hepatitis. U.S. Department of Health and Human Services, 2011.

A Review of FDA's Approach to Medical Product Shortages. U.S. Food and Drug Administration, October 31, 2011.

## **MEETINGS CONVENED FOR U.S. GOVERNMENT**

Naloxone App Competition Code-a-Thon, Silver Spring, MD, October 19-20, 2016.

Exploring Naloxone Uptake and Use, Public Meeting, Silver Spring, MD, July 1-2, 2015.

FDA Office of the Commissioner Joint Meeting of the Gastroenterology Urology Devices Panel and the Radiological Devices Panel of the Medical Devices Advisory Committee on Computed Tomography Colonography (CTC), Silver Spring, MD, September 9, 2013.

Role of Naloxone in Opioid Overdose Fatality Prevention, Public Meeting, Silver Spring, MD, April 12, 2012.

International Tobacco Regulators Conference, Leesburg, VA, November 14-16, 2011.

**MEDICAL PUBLICATIONS, BOOK CHAPTERS, ETC.**

Markon A, Wolfert B, Lurie P, et al. A comparison of caffeine adverse events in FDA and Poison Control Center databases. *New England Journal of Medicine* (under review).

Chahal HS, Szeto D, Chaudhry AH, Kim S, Sigelman DW, Lurie PG. Public disclosure of the filing of new drug and therapeutic biologics applications with the USFDA: a cross-sectional study. *British Medical Journal* (under review).

Lurie P. Suggestions for improving conflict of interest processes in US Food and Drug Administration Advisory Committees-past imperfect. *JAMA Internal Medicine* 2018. doi: 10.1001/jamainternmed.2018.1324.

Chai G, Xu J, Osterhout J, Liberatore MA, Miller KL, Wolff C, Cruz M, Lurie P, Dal Pan G. New opioid analgesic approvals and outpatient utilization of opioid analgesics in the United States, 1997 through 2015. *Anesthesiology* 2018;128:953-66..

Xu J, Gribble A, Sigelman D, Powell C, Lurie P. State Continuing Education Requirements for physicians and dentists, including requirements related to pain management and controlled substance prescribing. *Journal of Medical Regulation* 2017;103:12-20.

Chahal HS, Murray JS, Shimer M, Capella P, Presto R, Valdez ML, Lurie PG. The US Food and Drug Administration's tentative approval process and the global fight against HIV. *Journal of the International AIDS Society* 2017. doi: 10.1002/jia2.25019.

McKee AE, Markon AO, Chan-Tack KM, Lurie P. How often are drugs made available under FDA's Expanded Access Process approved? *Journal of Clinical Pharmacology* 2017;57(Suppl 10):S136-42.

Cruz ML, Xu J, Kashoki M, Lurie P. Publication and reporting of the results of post-market studies required by the US Food and Drug Administration in 2009-2013. *JAMA Internal Medicine* 2017;177:1207-10.

Faul M, Lurie P, Kinsman JM, Dailey MW, Crabaugh C, Sasser SM. Multiple naloxone administrations among Emergency Medical Service providers is increasing. *Prehospital Emergency Care* 2017;21:411-9.

Xu J, Emenanjo O, Ortwerth M, Lurie P. Association of appearance of conflicts of interest with voting behavior at FDA Advisory Committee meetings-a cross-sectional study. *JAMA Internal Medicine* 2017;177:1038-40.

Jarow J, Lurie P, Lemery S, Ikenberry S. Overview of FDA's Expanded Access Program for investigational drugs. *Drug Information Association Journal* 2017;51:177-9.

Xu J, Gill R, Cruz M, Staffa J, Lurie P. Effect of US Food and Drug Administration-approved pediatric labeling on dispensing of extended release oxycodone in the outpatient retail setting. JAMA Pediatrics 2016;170:1103-4. Presented before Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee, the Drug Safety and Risk Management Advisory Committee, and the Pediatric Advisory Committee Meeting, September 15-16, 2016.

Jones CM, Muhuri PK, Lurie PG. Trends in the nonmedical use of OxyContin, United States, 2006-2013. Clinical Journal of Pain 2016;Aug 10.

Jones CM, Lurie PG, Compton WM. Increase in naloxone prescriptions dispensed in US retail pharmacies since 2013. American Journal of Public Health 2016;106:689-90.

Jones CM, Lurie PG, Throckmorton DC. Effect of US Drug Enforcement Administration's rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing. JAMA Internal Medicine 2016;176:399-402.

Kim T, Lurie P, Pazdur R. US Food and Drug Administration efforts to facilitate the use of Expanded Access Programs. Journal of Clinical Oncology 2015;33:3979-80.

Klein R, Miller D, LoCicero C, Lurie P. Compassionate use exemption: expanded access to investigational drugs. Minnesota Physician 2015;July:1,18-9.

Lurie P, Chahal HS, Sigelman DW, Stacy S, Sclar J, Ddamulira B. Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study. BMJ 2015;350:h2758. doi: 10.1136/bmj.h2758.

Lurie P, Chan-Tack KM, Woodcock J. Expanded access to investigational drugs (letter). New England Journal of Medicine 2015;372:1473.

Jones CM, Lurie P, Woodcock J. Preventing prescription opioid abuse—reply (letter). Journal of the American Medical Association 2015;313:1060-1.

Jones CM, Lurie P, Woodcock J. Addressing prescription opioid overdose: data support a comprehensive policy approach. Journal of the American Medical Association 2014;312:1733-4.

Compton WM, Volkow ND, Throckmorton DC, Lurie P. Expanded access to opioid overdose intervention: research, practice, and policy needs (invited editorial). Annals of Internal Medicine 2013;158:65-6.

Throckmorton DC, Compton WM, Lurie P. Management of opioid analgesic overdose (letter). New England Journal of Medicine 2012;367:1371.



Shurin S, Atrash H, Boyle C, et al. The Department of Health and Human Services (HHS) Sickle Cell Disease (SCD) Initiative: Increasing Access and Improving Care. Poster presentation at American Society of Hematology meeting, September 23, 2011.

Hines JZ, Lurie P, Yu E, Wolfe S. Left to their own devices: breakdowns in United States medical device premarket review. PLoS Medicine 2010;7:e1000280.

Blum AB, Raiszadeh F, Shea S, Mermin D, Lurie P, Landrigan CP, Czeisler CA. US public opinion regarding proposed limits on resident physician work hours. BMC Medicine 2010;8:33.

Yu E, Lurie P. Randomized, controlled trials, not meta-analyses, remain standard for assessing depression device effectiveness (letter). Biological Psychiatry 2010;67:e29.

Yu E, Lurie P. Transcranial magnetic stimulation not proven effective (letter). Biological Psychiatry 2010;67:e13.

Floyd JS, Barbehenn E, Lurie P, Wolfe SM. Case series of liver failure associated with rosiglitazone and pioglitazone (letter). Pharmacoepidemiology and Drug Safety 2009;18:1238-43.

Lurie P. [Direct-to-Consumer] Advertising harms patients and should be tightly regulated. Journal of Law, Medicine & Ethics 2009 Fall;37:444-50.

Larson M, Lurie P, Marcus B, Wolfe S. Survey of state medical and osteopathy board disciplinary web sites in 2006. Health Matrix Cleveland 2009;19:121-36.

Hines JZ, Lurie P, Wolfe SM. Post hoc analysis does not establish effectiveness of [repetitive transcranial magnetic stimulation] for depression (letter). Neuropsychopharmacology 2009;34:2053-4.

Ross JS, Nazem AG, Lurie P, Lackner JE, Krumholz HM. Updated estimates of pharmaceutical company payments to physicians in Vermont. Journal of the American Medical Association 2008;300:1998-2000.

Natanson C, Lurie P, Wolfe SM. Hemoglobin-based blood substitutes and risk of myocardial infarction and death (letter). Journal of the American Medical Association 2008; 300:1300.

Natanson C, Kern S, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. Journal of the American Medical Association 2008;299:2304-12.

Basu S, Lurie P. [Ethics of] Hepatitis E vaccine [trials in Nepal] (letter). New England Journal of Medicine 2007;356:2421-2.



Lurie P, Wolfe SM. The developing world as the “answer” to the dreams of pharmaceutical companies: the Surfaxin story. In: Lavery JV, Grady C, Wahl ER, Emanuel EJ. *Ethical Issues in International Biomedical Research*. Oxford University Press, Oxford, 2007, pp. 159-70.

Ross JS, Lackner JE, Lurie P, Gross CP, Krumholtz HM. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. *Journal of the American Medical Association* 2007;297:1216-23.

Tapley A, Lurie P, Wolfe SM. Sub-optimum use of FDA drug Advisory Committees (letter). *Lancet* 2006;368:2210.

Caughey AB, Urato AC, Lurie P. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial (letter). *Obstetrics and Gynecology* 2006;108:1550.

Michaels D, Lurie P, Montforton C. Lung cancer mortality in the German chromate industry, 1958 to 1998 (letter). *Journal of Occupational and Environmental Medicine* 2006;48:995-7.

Lurie P. Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings. *MedGenMed* 2006;8:22.

Lurie P, Zieve A. Sometimes the silence can be like the thunder: access to pharmaceutical data at the FDA. *Law and Contemporary Problems* 2006;69:85-97.

Cha SS, Ross JS, Sacajiu G, Lurie P. Description of a research-based health activism curriculum for medical students. *Journal of General Internal Medicine* 2006; 21:12 1325.

Jung P, Lurie P, Wolfe SM. U.S. physicians disciplined for criminal activity. *Health Matrix Cleveland* 2006;16:335-50.

Stine N, Lurie P, Stine N. Responding to three articles regarding vagus nerve stimulation (VNS) for depression (letter). *Biological Psychiatry* 2006;60:1382.

Lurie P. The US FDA at a crossroads. *Regulatory Affairs Journal – Pharma* 2006; 17:427-8.

Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration drug advisory committee meetings. *Journal of the American Medical Association* 2006;295:1921-8.

Michaels D, Montforton C, Lurie P. Selected science: an industry campaign to undermine an OSHA hexavalent chromium standard. *Environmental Health* 2006;5:5.

Lurie P, Tran T, Wolfe SM, Goodman R. Violations of exhibiting and FDA rules at an American Psychiatric Association annual meeting. Journal of Public Health Policy 2005;26:389-99.

Dweck A, Lurie P, Michaels D, Wolfe S. Hexavalent chromium study's conclusions unjustified (letter). Journal of Occupational and Environmental Medicine 2005;47:980-1.

Lurie P, Wolfe SM. Misleading data analyses in salmeterol (SMART) study (letter). Lancet 2005;366:1261-2.

Lurie P, Greco DB. US exceptionalism comes to research ethics. Lancet 2005;365:1117-9. (Reprinted as: Lurie P, Greco DB. Ética na pesquisa clínica: novas pressões dos EUA para diminuir os requisitos éticos para a pesquisa clínica em países em desenvolvimento. Boletim de Vacinas Anti HIV/AIDS 2005;June:20-2.

Ardati A, Stolley P, Knapp DE, Wolfe SM, Lurie P. Statin-associated rhabdomyolysis (letter). Pharmacoepidemiology and Drug Safety 2005;14:287.

Wolfe SM, Sasich LD, Lurie P, et al. Worst Pills, Best Pills. Pocket Books, New York: 2005.

Lurie P. Review of "Science in the Public Interest: Has the Lure of Profits Corrupted Biomedical Research?" by Sheldon Krimsky. Journal of Public Health Policy 2004;25:444-7.

Herxheimer A, Mansfield PR, Bogaert M, et al. Open letter to Annette King, Minister of Health, New Zealand (letter). British Medical Journal 2004;329:51.

Tepper OM, Lurie P, Wolfe SM. Medical education. Courses in research-based health activism. Virtual Mentor, January 2004. Available at: <http://virtualmentor.ama-assn.org/2004/01/medu1-0401.html>.

Tsai AC, Lurie P, Sehgal AR. An outbreak of web sites selling ciprofloxacin following an outbreak of anthrax by mail. American Journal of Medicine 2002;113:424-7.

Ajuwon AJ, McFarland W, Hudes ES, Adedapo S, Okikiolu T, Lurie P. HIV risk-related behavior, sexual coercion, and implications for prevention strategies among female apprentice tailors, Ibadan, Nigeria. AIDS and Behavior 2002; 6:229-35.

Lurie P, Wolfe SM. Continuing exposure to hexavalent chromium, a known lung carcinogen: an analysis of OSHA compliance inspections, 1990-2000. American Journal of Industrial Medicine 2002;42:378-83.

Anderson M, Karasz A, Lurie P. The pharmaceutical industry and disease mongering. Deja vu all over again (letter). British Medical Journal 2002;325:216.

Lurie P. Clinical research paradox. Good Clinical Practice Journal 2001; Oct:9-10.

Rich JD, Burris S, Lurie P. Sterile Injection Equipment To Prevent HIV Infection (letter). Annals of Internal Medicine 2001;135:299.

Vlahov D, Des Jarlais DC, Goosby E, Hollinger PC, Lurie PG, Shriver MD, Strathdee SA. Needle exchange programs for the prevention of human immunodeficiency virus infection: epidemiology and policy. American Journal of Epidemiology 2001;154(12 Suppl):S70-7.

Barbehenn EK, Lurie P, Wolfe SM. Osteosarcoma risk in rats using PTH 1-34 (letter). Trends in Endocrinology and Metabolism 2001;12:383.

Lurie P, Wolfe SM. Outcomes of a trial of HIV-1 immunogen in patients with HIV infection (letter). Journal of the American Medical Association 2001;285:2193-5.

Burris S, Lurie P, Ng M. Harm reduction in the health care system: the legality of prescribing and dispensing syringes to drug users. Health Matrix Cleveland 2001;11:5-64.

Barbehenn E, Lurie P, Wolfe SM. Alosetron for irritable bowel syndrome (letter). Lancet. 2000;356:2009-10.

Burris S, Lurie P, Abrahamson D, Rich JD. Physician prescribing of sterile injection equipment to prevent HIV infection: time for action. Annals of Internal Medicine 2000;133:218-26.

Xiaoming S, Yong W, Choi K-H, Lurie P, Mandel J. Integrating HIV prevention education into existing family planning services: results of a controlled trial of a community-level intervention for young adults in rural China. AIDS and Behavior 2000; 4:103-10.

Smith M, Gertz E, Alvarez S, Lurie P. The content and accessibility of sex education information on the Internet. Health Education & Behavior 2000;27:684-94.

Sobel HL, Lurie P, Wolfe SM. Lead in candle wicks (letter). Journal of the American Medical Association 2000;284:2189-90.

Wolfe SM, Lurie P, Sasich LD, Barbehenn E. Information on thiazolidinediones (letter). Lancet 2000;356:254-5.

Lurie P, Wolfe SM. Ethics require the inclusion of condoms and counseling in anti-HIV microbicide trials (letter). American Journal of Public Health 2000;90:1154-5.

Sobel HL, Lurie P, Wolfe SM. Lead exposure from candles. Journal of the American Medical Association 2000;284:180.

Lane S, Lurie P, Bowser B, Kahn J, Chen D. The coming of age of needle exchange: a history through 1993. In Harrison L, Inciardi J, eds. Harm Reduction: National and International Perspectives. Sage Publications, Thousand Oaks, CA, 2000.

Aftab M, Kolben D, Lurie P. International cigarette labeling practices. Tobacco Control 1999;8:368-72.

Lurie P, Sasich LD. Safety of FDA-approved drugs (letter). Journal of the American Medical Association 1999;282:2297-8.

Lurie P, Wolfe SM. HIVNET nevirapine trials (letter). Lancet 1999;354:1816-7.

Lurie P, Wolfe SM. Proposed revisions to the Declaration of Helsinki: paving the way for globalization in research (invited editorial). Western Journal of Medicine 1999;171:6.

Lurie P, Wolfe SM. Should research ethics change at the border? (letter) Medical Journal of Australia 1999;171:167-8.

Lurie M, Lurie P, IJsselmuiden C, Gray G. Denying effective antiretroviral drugs to HIV-positive pregnant women-- the national government's flawed decision. South African Medical Journal 1999;89:621-3.

Lurie P, Wolfe SM. Tuskegee as a metaphor (letter). Science 1999;285:47-8.

Lurie P, Wolfe SM. Science, ethics, and future of research into maternal-infant transmission of HIV-1 (letter). Lancet 1999;353:1878-9.

Lurie P, Miller S, Hecht FM, Chesney M, Lo B. Postexposure prophylaxis following HIV exposure (letter). Journal of the American Medical Association 1999;281:1270.

Lurie P. Falling FDA standards: the Health Research Group study. Medical Crossfire 1999;April:53-6.

Neighbors K, Oraka C, Shih L, Lurie P. Awareness and utilization of the hepatitis B vaccine among young men in the Ann Arbor area who have sex with men. Journal of American College Health 1999;47:173-8.

Lurie P, Miller S, Hecht FR, Chesney M, Lo B. Post-exposure prophylaxis after non-occupational exposure to the human immunodeficiency virus: clinical, ethical and policy implications. Journal of the American Medical Association 1998;280:1769-73.

Lurie P. Dr. Lurie replies [to letters regarding his editorial on the Montreal and Alaska needle exchange studies] (letter). American Journal of Epidemiology 1998;148:715-6.

Drucker E, Lurie P, Wodak A, Alcabes P. Measuring harm reduction: the effects of needle and syringe exchange programs and methadone maintenance on the ecology of HIV. AIDS 1998;12(suppl A):S217-30.

Lurie P, Gorsky R, Jones TS, Shomphe L. An economic analysis of needle exchange and pharmacy-based programs to increase sterile syringe availability for injection drug users. Journal of Acquired Immune Deficiency Syndromes and Human Retroviruses 1998;18(Suppl 1):S126-32.

Lurie P, Jones TS, Foley J. A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution? Journal of Acquired Immune Deficiency Syndromes and Human Retroviruses 1998;18(Suppl 1):S45-51.

Holtgrave DR, Jones TS, Lurie P, Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. Journal of Acquired Immune Deficiency Syndromes and Human Retroviruses 1998;18(Suppl 1):S133-8.

Caulkins JP, Kaplan EH, Lurie P, O'Connor T, Ahn S-H. Can difficult-to-reuse syringes reduce the spread of HIV among IDUs? Interfaces 1998;28:23-33.

Lurie P, Wolfe SM. Ethics of placebo-controlled trials of zidovudine to prevent the perinatal transmission of HIV in the Third World (letter). New England Journal of Medicine 1998;338:840-1.

Lurie P, Wolfe SM. Comparison of short and long zidovudine regimens is appropriate (letter). British Medical Journal 1998;316:626.

Lurie P, Wolfe SM. Ethics of HIV trials (letter). Lancet 1998;351:220.

Lurie P. Quando a ciencia e a politica colidem: a resposta do governo federal dos EUA aso programas de troca de seringas. In: Bastos FI, Mesquita F, eds. Troca de seringas: ciencia, debate e saude publica. Brasilia: Ministerio de Saude, 1998.

Lurie P. Le Mystere de Montreal (invited editorial). American Journal of Epidemiology 1997;146:1-4.

Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. New England Journal of Medicine 1997;337:853-6. (Reprinted in Steinbock B, Arras JB, London AJ, eds. Ethical Issues in Modern Medicine. McGraw-Hill, New York, 2003; Schuklenk U, ed. AIDS: Society, Ethics and Law. Ashgate, Aldershot, 2000; and Oakley J, ed. Bioethics. Ashgate, Aldershot, 2009.)

Fuentes-Afflick E, Lurie P. Low birth weight and Latino ethnicity: examining the epidemiologic paradox. Archives of Pediatrics & Adolescent Medicine 1997;151:665-74.

Miller S, King T, Lurie P, Choitz P. Certified nurse-midwife and physician collaborative practice: piloting a survey on the Internet. Journal of Nurse-Midwifery 1997;42:308-15.

Lurie P, DeCarlo P. US HIV prevalence estimates: why the delay in publication? (letter). American Journal of Public Health 1997;87:873-4.

Lurie P. Reducao de danos: a experiencia Norte-Americana. In Rebiero MdeM, Seibel SD (eds.). Drogas: Hegmonia do Cinismo. Fundacao Memorial da America Latina, Sao Paulo, 1997.

Lindan CP, Lieu TX, Giang LT, et al. Rising HIV infection rates in Ho Chi Minh City herald emerging AIDS epidemic in Vietnam. AIDS 1997;11(suppl. 1):S5-14.

Nzyuko S, Lurie P, McFarland W, Leyden W, Nyamwaya D, Mandel J. Adolescent sexual behavior along the Trans-Africa Highway in Kenya. AIDS 1997;11(suppl. 1):S21-6.

Wodak A, Lurie P. A tale of two countries: attempts to control HIV among injecting drug users in Australia and the United States. Journal of Drug Issues 1996;27:117-34.

Lurie P, Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the United States. Lancet 1997;349:604-8.

Lurie P, Alary M, Andrade TM, et al. Letter to Donna Shalala (letter). International Journal of Drug Policy 1996;7:62-63. Reprinted in Alcoholism & Drug Abuse Weekly, February 1996, and Resolute, May 1996.

Coates TJ, Chesney M, Folkman S, et al. Designing behavioural and social science to impact practice and policy in HIV prevention and care. International Journal of STD & AIDS 1996;7(Suppl. 2):2-12.

Stryer D, Lurie P, Bero LA. Dear Doctor ... regarding calcium channel blockers (letter). Journal of the American Medical Association 1996;275:517.

Lurie P. The search for an AIDS vaccine (book review). Journal of the American Medical Association 1996;275:329.

Loue S, Lurie P, Lloyd L. Ethical issues raised by needle exchange programs. Journal of Law, Medicine and Ethics 1995;23:382-8.

Lurie P. When science and politics collide: the federal response to needle-exchange programs. Bulletin of the New York Academy of Medicine 1995;72:380-396.

Paone D, Des Jarlais DC, Clark J, et al. Syringe exchange programs -- United States, 1994-1995. Morbidity and Mortality Report 1995;44:684-685. Reprinted in Journal of the American Medical Association 1995;274:1260.

Lurie P. Correction: Medical News & Perspectives on needle exchange programs (letter). Journal of the American Medical Association 1995;274:684.

Lurie P, Hintzen P, Lowe RA. Response to the World Bank (letter). AIDS 1995;9:983-4.

Lurie P, Fernandes MEL, Hughes V, et al. Socioeconomic status and risk of HIV-1, syphilis and hepatitis B infection among commercial sex workers in Sao Paulo State, Brazil. AIDS 1995;9(Suppl. 1):S31-7.

Sandala L, Lurie P, Sunkutu MR, Chani EM, Hudes ES, Hearst N. "Dry sex" and HIV infection among women attending a sexually transmitted diseases clinic in Lusaka, Zambia. AIDS 1995;9(Suppl. 1):S61-8.

Lurie P, Avins A, Phillips KA, Kahn JG, Lowe RA, Ciccarone D. The cost-effectiveness of voluntary counseling and testing of hospital patients for HIV (letter). Journal of the American Medical Association 1995;274:130.

Lurie P, Hintzen P, Lowe RA. Socioeconomic obstacles to HIV prevention and treatment in developing countries: the roles of the International Monetary Fund and the World Bank. AIDS 1995;9:539-46. (Reprinted in: Kalipeni E, Craddock S, Oppong JR, Gyosh J. HIV & AIDS in Africa: Beyond Epidemiology. Blackwell Publishing, Oxford, 2004.)

Chesney MA, Lurie P, Coates, TJ. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials. Journal of Acquired Immune Deficiency Syndromes 1995;9:30-5.

Lurie P, Avins A, Phillips KA, Kahn JG, Lowe RA, Ciccarone D. The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infection. Journal of the American Medical Association 1994;272:1832-8.

Lurie P, Kahn JG, Bowser B, et al. The University of California Needle Exchange Program Evaluation Project: Methods, conclusions, and recommendations. In: National Research Council. Proceedings: workshop on needle exchange and bleach distribution programs, National Academy Press, Washington, DC, 1994.

Phillips KA, Lowe RA, Kahn JG, Lurie P, Avins AL, Ciccarone D. Potential cost of screening surgeons for HIV (letter). Journal of the American Medical Association 1994;272:434-5.

Phillips KA, Lowe RA, Kahn JG, Lurie P, Avins A, Ciccarone D. The cost-effectiveness of human immunodeficiency virus testing of health care workers in the United States. Journal of the American Medical Association 1994;271:851-8.



Lurie P, Bishaw M, Chesney MA, et al. Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries. Journal of the American Medical Association 1994;271:295-301. (Reprinted in: Schuklenk U, ed. AIDS: Society, Ethics and Law. Ashgate, Aldershot, 2000.)

Lurie P, Newman TB, Hulley SB. Caution over journal supplements (letter). British Medical Journal 1993;307:1140-1.

Lurie P, Reingold AL, Bowser B, et al. The Public Health Impact of Needle Exchange Programs in the United States and Abroad, Summary and Volume I, University of California, September 1993.

Lurie P, Reingold AL, Bowser B, et al. The Public Health Impact of Needle Exchange Programs in the United States and Abroad, Volume II, University of California, October 1993.

Lurie P, Chen D, Needle Exchange Program Evaluation Project. A review of programs in North America. In Stryker J, Smith MD, eds. Needle Exchange, Henry J. Kaiser Family Foundation, Menlo Park, CA, 1993.

Lane SD, Needle Exchange Program Evaluation Project. A brief history. In Stryker J, Smith MD, eds. Needle Exchange, Henry J. Kaiser Family Foundation, Menlo Park, CA, 1993.

Ahmad SR, Wolfe SM, Lurie P. Treatment of acute pediatric diarrhea (letter). American Pharmacy 1993;NS33:5-6.

Lurie P, Lowe RA, Avins AL, et al. HIV infection among patients in U.S. acute care hospitals -- strategies for the counseling and testing of hospital patients (letter). New England Journal of Medicine 1992;327:1815-6.

Lurie P, Franklin RM, Kahn JG. The Unkindest Cut of All: Proposed Cuts in Mental Health, Dental, and Drug Treatment Services. San Francisco Coalition for Public Health Services, September 23, 1992.

Kahn JG, Lurie P, Grumbach KG. Consumer competence and the reform of American health care (letter) Journal of the American Medical Association 1992;268:1265-6.

Wolfe SM, Lurie P. Regulation of benzodiazepine prescription (letter) Journal of the American Medical Association 1992;268:472.

Lurie P, Kahn JG, Wolfe SM. Regulation of benzodiazepine prescription (letter) Journal of the American Medical Association 1992;268:472-3.



Lurie P. Testimony before Grievance Hearing on Critikon *Protectiv* intravenous catheter, November 15, 1991. Hearing before the Subcommittee on Regulation, Business Opportunities, and Energy of the Committee on Small Business, House of Representatives, February 7, 1992, p. 100-114. (Reprinted in Healthcare Hazardous Materials Management 1992;5:1-4.)

Lurie P, Lee PR. Fifteen solutions to the problems of prescription drug abuse. Journal of Psychoactive Drugs 1991;23:349-57.

Lurie P, Kahn JG. Taking a Bite out of Services: Proposed Cuts in Dental Services, the Poison Control Center, and the Evening General Medical Clinic. San Francisco Coalition for Public Health Services, June 24, 1991.

Lee PR, Lurie P. A health business? World health and the pharmaceutical industry (book review). Lancet 1991;337:1209-10.

Lee PR, Lurie P, Silverman MM, Lydecker M. Drug promotion and labeling in developing countries: An update. Journal of Clinical Epidemiology 1991;44(Suppl. II):49-55.

Lurie P, Kahn J. Cut Now, Pay Later: A Study of the Proposed State Budget Huts on the Health of Poor San Franciscans. San Francisco Coalition for Public Health Services, 25 August, 1990.

Lurie P. The HIV epidemic and training in internal medicine (letter). New England Journal of Medicine 1990;322:1392.

Lee PR, et al. HIV Disease: Health Care Policy Issues. A planning paper prepared for the American Foundation for AIDS Research. Institute for Health Policy Studies, University of California, San Francisco, February 7, 1990.

Lurie P. Toward optimal use of radiographs: should admission and preoperative chest films be routine? Postgraduate Medicine 1987;82:209-16.

Lurie P. Anabolic steroids: a review of safety and efficacy. Werkgroep Medische Ontwikkelings Samenwerking, Amsterdam, Netherlands, August 1987.

Lurie P. Changing the complexion of apartheid: A study of skin lightener use in Gazankulu. Report prepared for Health Services Development Unit, University of Witwatersrand Medical School, Johannesburg, South Africa, May 1987.

Lurie P. The acquired immunodeficiency syndrome: Transmission, epidemiology and natural history. Internal background paper prepared for Industrial Health Research Group, Department of Sociology, University of Cape Town, South Africa, May 22, 1987.

Lurie P. The acquired immunodeficiency syndrome: Selected public health issues and implications for the doctor-patient relationship. Internal background paper prepared for Industrial Health Research Group, Department of Sociology, University of Cape Town, South Africa, May 22, 1987.

Lurie P. AIDS and labour policy. South African Labour Bulletin 1987;12: 80-8.

Lurie P, Cary D, Tanio C, Wolfe SM. Paradigms for Change: A Public Health Textbook for Medical, Dental, Pharmacy and Nursing Students, Public Citizen Health Research Group, Washington, D.C. (unpublished).

### **LETTERS TO THE EDITOR AND BLOGS WITH CENTER FOR SCIENCE IN THE PUBLIC INTEREST**

Lurie P. There is a nutritional imbalance at the FDA. The Hill, March 9, 2018.

Lurie P. Failing to keep up with consumers — the grocery lobby is losing members. The Hill, February 13, 2018.

Lurie P. FDA Should Ignore Big Salt's Delay Tactics. Medium, February 6, 2018.

Lurie P. Leave drug safety to the FDA, not the assistant secretary of defense. The Hill, November 14, 2017.

Lurie P. This administration has contempt for public health. The Hill, October 25, 2017.

### **LETTERS TO THE EDITOR AND BLOGS WITH U.S. GOVERNMENT**

Lurie P. FDA's Naloxone App Prize Competition celebrates innovation in search of technological solutions to the opioid epidemic (blog), December 15, 2016.

Lurie P. FDA more efficient now, not less. The Hill, September 20, 2016.

Lurie P. FDA is trying to save lives via safe, effective drugs. Wall Street Journal, December 14, 2015.

Lurie P. Why FDA should oversee laboratory developed tests (blog), November 16, 2015.

Lurie P. Naloxone – FDA hosts meeting to discuss expanded use of overdose medicine (blog), June 30, 2015.

Lurie P. FDA working to meet needs of patients. San Diego Union Tribune, June 3, 2015.

Lurie P. A big step to help the patients most in need (blog), February 4, 2015.

**TESTIMONY/PRESENTATIONS BEFORE GOVERNMENT BODIES**

Lurie P. Informing future actions to promote optimal health. Presentation before Food Forum, National Academies of Sciences, Engineering, and Medicine, Washington, DC, April 19, 2018.

Lurie P. Statement before the Senate Committee on Homeland Security and Government Affairs on FDA's Expanded Access Program, September 22, 2016.

Faul M. Trends in multiple naloxone administrations among EMS personnel. Presented before Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee, October 5, 2016.

Lurie P. An Overview of FDA's Expanded Access Process and the New Individual Patient Expanded Access Application. DDI Webinar Series. July 11, 2016.

Lurie P. Addressing Opioid Overdose in Rural Communities – A Federal Perspective. Rural Opioid Overdose Reversal Grant Program Partnership Meeting, Washington, DC, April 25, 2016.

Lurie P. Scope/Nature of the U.S. Opioid Problem. Congressional Briefing/George Washington Department of Emergency Medicine Grand Rounds, Washington, DC, April 13, 2016.

Lurie P. Advancing Policy and Practice: A 50-State Convening to Prevent Opioid Overdose and Addiction. Department of Health and Human Services. Arlington, VA, September 17, 2015.

Lurie P. Revised Individual Patient Expanded Access Application Form and Related Activities. Friends of Cancer Research Meeting on Expanded Access, February 4, 2015.

Lurie P. A Review of FDA's Approach to Medical Product Shortages. Massachusetts Medical Society, Boston, MA, May 17, 2012.

Lurie P. Using Data and Analysis to Promote the Public Health at FDA. Office of Health and Constituent Affairs Conference, May 13, 2014.

Lurie P. HHS efforts to mitigate the risks associated with prescription drug abuse. Presented before the Food and Drug Administration's Drug Safety Board, March 15, 2012.

Lurie P. A Review of FDA's Approach to Medical Product Shortages. American Bar Association, February 24, 2012.

Lurie P. Opening Remarks, Expanded Access to Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection, Rockville, MD, April 30, 2010.

Lurie P. Importance of Consumer Representatives on FDA Advisory Committees and Panels, Remarks at Public Meeting, Rockville, MD, April 30, 2010.

Lurie P, Peabody H. Testimony before the FDA Transparency Task Force, June 24, 2009.

Lurie P, Hines J. Testimony before the Subcommittee on Health, Committee on Energy and Commerce, United States House of Representatives on regulation of medical devices, June 18, 2009.

Lurie P, Hines J. Testimony before the Neurological Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food and Drug Administration on DuraSeal Xact Sealant System for Spinal Use, May 14, 2009.

Hines J, Lurie P. Testimony before Orthopedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee on Collagen Scaffold, November 14, 2008.

Necochea A, Lurie P. Testimony before FDA hearing on cough and cold remedies for children, October 2, 2008.

Lurie P. Presentation before the Institute of Medicine Committee on Optimizing Graduate Medical Trainee (Resident) Schedules to Improve Patient Safety, December 3, 2007.

Lurie P. Presentation before the Institute of Medicine Committee on Conflict of Interest in Medical Research, Education, and Practice, November 5, 2007.

Lurie P, Barbehenn E. Comments before the Joint Meeting of the Non-Prescription Drugs and Pediatrics Advisory Committees of the Food and Drug Administration on the availability of over-the-counter pediatric cough and cold formulations, October 19, 2007.

Lurie P, Yu E. Testimony before the FDA Circulatory Systems Devices Panel meeting on the resorbable adhesion barrier REPEL-CV, September 19, 2007.

Lurie P, Ross JS, Rosenbaum AH, Krigel J. Testimony before the Senate Special Committee on Aging on State Laws Requiring Disclosure of Pharmaceutical Company Payments to Physicians, June 27, 2007.

Lurie P. Testimony before the Health Subcommittee of the Committee on Energy and Commerce, U.S. House of Representatives on Programs Affecting Safety and Innovation in Pediatric Therapies, May 22, 2007.

Lurie P. Testimony before the Texas House of Representatives Health and Human Services Committee on the efficacy of needle exchange programs, May 14, 2007.

Lurie P. Testimony before the Texas Senate Committee on Public Health on the efficacy of needle exchange programs, April 12, 2007.

Lurie P, Park S. Testimony before the FDA Neurological Devices Panel of the Medical Devices Advisory Committee on repetitive transcranial magnetic stimulation (rTMS), Duraseal, and vagus nerve stimulation (VNS), January 26, 2007.

Lurie P. Testimony before the New Jersey Senate Health, Human Services and Senior Citizens Committee on the efficacy of needle exchange programs, September 18, 2006.

Lurie P, Barbehenn E. Testimony before FDA Peripheral and Central Nervous System Drugs Advisory Committee Meeting on Rivastigmine (Exelon) for Dementia Associated with Parkinson's Disease, May 17, 2006.

Lurie P. Testimony before the Senate Special Committee on Aging on the impact of direct-to-consumer drug advertising on seniors' health and health care costs, September 29, 2005.

Lurie P, Barbehenn E. Testimony before FDA's Endocrinologic and Metabolic Drugs Advisory Committee Meeting on Muraglitazar (Pargluva), September 9, 2005.

Lurie P. Testimony before Food and Drug Administration Public Meeting on Levothyroxine Sodium Therapeutic Equivalence, May 23, 2005.

Lurie P. Testimony before FDA Oncologic Drugs Advisory Committee on safety and efficacy of gefitinib (Iressa), March 3, 2005.

Lurie P, Barbehenn E. Testimony before the FDA's Cardiovascular and Renal Drugs Advisory Committee Hearing on Ximelagatran (Exanta), September 10, 2004.

Lurie P. Testimony before a Joint Meeting of the United States House of Representatives Committee on Government Reform and Committee on Agriculture on Mad Cow Disease Surveillance, July 14, 2004.

Lurie P. Testimony before the Health and Human Services Taskforce on Drug Importation, March 19, 2004.

Lurie P. Statement before National Academy of Sciences' Committee on Clinical Research Involving Children, July 9, 2003.

Lurie P. Statement before FDA's Nonprescription Drugs Advisory Committee on safety issues related to acetaminophen, September 19, 2002.

Lurie P. Statement before the FDA's Endocrinologic and Metabolic Drugs Advisory Committee on teriparatide (Forteo), July 27, 2001.

Lurie P. Testimony before the Consumer Affairs, Foreign Commerce and Tourism Subcommittee of the Senate Commerce, Science and Transportation Committee on Mad Cow Disease, April 4, 2001.

Lurie P. Testimony before the Senate Subcommittee on African Affairs, Committee on Foreign Relations on six steps that can ease the AIDS epidemic in Sub-Saharan Africa, February 24, 2000.

Lurie P. Expert witness in trial of four persons arrested for exchanging syringes. Fresno, CA, November 5, 1999.

Lurie P. Statement before US House of Representatives Committee on Government Reform, Subcommittee on Criminal Justice, Drug Policy, and Human Resources on compulsory licensing and parallel importing of AIDS drugs for developing countries, July 22, 1999.

Lurie P. The use of placebos in clinical trials. US Food and Drug Administration Lecture Series, Rockville, MD, April 21, 1999.

Lurie P, Wolfe SM. Deciding whether a trial in a developing country is ethical. Presentation before WHO/NIH/CDC/PAHO Consultation on Ethical Aspects of HIV Vaccine Trials Conducted in Developing Countries and Sponsored by Developed Countries, Washington, DC, May 11, 1998.

Lurie P, Wolfe SM. Testimony before the Committee on Government Reform and Oversight, U.S. House of Representatives on inappropriate use of placebos in human experiments, April 22, 1998.

Lurie P. Implications of the Centers for Disease Control/Thailand study. Congressional Briefing on Perinatal Trials -- Ethics and Implications, U.S. House of Representatives, March 3, 1998.

Lurie P. Presentation before Newark City Council on needle exchange and pharmacy-based interventions to prevent HIV transmission among injection drug users, Newark, NJ, January 14, 1998.

Lurie P, Wolfe SM. Testimony before the Subcommittee on Human Resources, Committee on Government Reform and Oversight, U.S. House of Representatives, on HIV vaccine trials and a National Institute of Health-funded needle exchange program in Alaska, May 8, 1997.

Lurie P. Testimony before the Labor/HHS, Education, and Related Agencies Subcommittee of the Senate Appropriations Committee on the efficacy of needle exchange programs, June 6, 1996.

Lurie P. Effectiveness of needle exchange and pharmacy-based programs in reducing the spread of HIV among injection drug users. Presented before Getting to the Point: the Role of Sterile Syringes in HIV Prevention, National Conference of State Legislatures, Washington, DC, May 9, 1996.

Lurie P, Wolfe SM. Harmony or disharmony? Protecting consumer interests in global harmonization. Presented before What we've done ... where we're going; Review and Forecast of the [International Conference on Harmonization], Rockville, MD, April 17, 1996.

Coates T, Lurie P. The U.S. role in confronting the global epidemic. Presentation before the Subcommittee on Prevention of the Presidential Advisory Committee on HIV/AIDS, San Francisco, CA, November 20, 1995.

Lurie P. Vaccine development: behavioral and policy aspects. Presentation before the Subcommittee on Prevention of the Presidential Advisory Committee on HIV/AIDS, San Francisco, CA, November 20, 1995.

Lurie P. Injection drug transmission. Presentation before the Subcommittee on Prevention of the Presidential Advisory Committee on HIV/AIDS, San Francisco, CA, November 19, 1995.

Lurie P. Testimonies on needle exchange programs before Boards of Supervisors, City Councils or Health Committees of Alameda, Berkeley, Daly City, Oakland, Sacramento, Salinas, Santa Cruz, Tacoma, 1993-95; written comments submitted to New Hampshire Senate Health and Human Services Committee, April 19, 1995.

Lurie P. Expert witness in trial of five persons arrested for exchanging syringes, Oakland, CA, March 6, 1995.

Lurie P. Contemporary Legal Issues [pertaining to syringe availability for injection drug users]. Presented at National Association of Boards of Pharmacy Annual Meeting, Dallas, TX, May 2, 1995.

Lurie P. Testimony before Colorado Governor's AIDS Task Force on needle exchange and needle availability, Denver, CO, May 1, 1995.

Lurie P. Testimony before Texas Senate Health and Human Services Committee on needle exchange, Austin, TX, April 5, 1995.

Lurie P. Wolfe SM. Consumer Interests in Global Harmonization. Presented at The ICH Process: An Orientation and Progress Report for US Stakeholders. Washington, DC, September 22, 1994.

Lurie P. Prevention, Education and Treatment Strategies. Presentation at Reducing Misuse and Abuse of Prescription Drugs: What Role Should Universities Play? New York State Department of Health, Albany, NY, September 20, 1994.

Lurie P. Expert witness at trial of person arrested for exchanging syringes, Berkeley, CA, March 1-3, 1994.

Lurie P. The Public Health Impact of Needle Exchange Programs in the United States and Abroad. Address to United States Conference of Mayors, Washington, DC, January 26, 1994.

Lurie P. University of California Study: Description of Methods and Impact on HIV. Presented at Workshop on Needle Exchange and Bleach Distribution Programs, National Academy of Sciences, Baltimore, MD September 27 and 28, 1993.

Lurie P. Testimony on Triplicate Benzodiazepine Prescription Programs before the Controlled Substances Prescription Advisory Council of the California State Legislature, Los Angeles, CA, September 23, 1993.

Lurie P. A Research Agenda for Needle Exchange and Availability. Presentation before Institute of Medicine Committee on Substance Abuse and Mental Health Issues in AIDS Research, San Francisco, CA, July 19, 1993.

Lurie P. Centers for Disease Control and Prevention Needle Exchange Program Evaluation Project. Presented at Panel on Needle Exchange and Bleach Distribution Programs, National Academy of Sciences, Washington, DC, June 28, 1993.

Lurie P. Testimony on over-the-counter antidiarrheal drugs before the Food and Drug Administration Nonprescription Drugs Advisory Committee, Washington, DC, April 9, 1993.

Lurie P. Evaluation of needle exchange programs. Presentation before Division of HIV/AIDS and STD, Washington State Department of Health, Tacoma, WA, October 23, 1992.

Lurie P. Testimony before San Francisco Board of Supervisors on impact of proposed health budget cuts, September 1992.

Lurie P. Testimony before San Francisco Board of Supervisors and Finance Committee on impact of proposed health budget cuts, June-July, 1991.



Lurie P. Testimony before San Francisco Board of Supervisors and Finance Committee on impact of proposed health budget cuts, July-August, 1990.

Lurie P. Testimony before San Francisco Board of Supervisors and Finance Committee on impact of proposed health budget cuts, July-August, 1989.

Wolfe SM, Bargmann E, Lurie P. Testimony before FDA Arthritis Advisory Committee on phenylbutazone (Butazolidine), Public Citizen Health Research Group, May 25, 1984.

**AVAILABLE UPON REQUEST (Produced with UCSF, University of Michigan and Public Citizen's Health Research Group)**

Scientific conference oral presentations and abstracts (38 items)

Publications with Public Citizen's Health Research Group

    Pharmaceutical safety and efficacy (58 items)

    Medical devices (15 items)

    Healthcare delivery policy (68 items)

    Food safety (9 items)

    Occupational safety and health (22 items)

Additional articles, opinion pieces and other lay publications (78 items)

Additional letters to the editor (26 items)

Educational materials (5 items)